Who
Alexander W. Casdin
Director
Company insider
Files Form 4 as: Director, Erasca; Director, Sientra; Director, Ignyta; Director, Dusa Pharmaceuticals.
In numbers
- Trades disclosed
- 46
- Buys
- 7
- Sells
- 0
- Bought
- $7.1M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 27 Feb 2009
- Last trade
- 26 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,872 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,872 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 1 Jan 2025filed 2 Jan 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,877 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 21 May 2024filed 22 May 2024 | ERAS ErascaBiotechnology | SEC FORM 4 Bought | $182K80,000 at $2.27 | filing |
| 1 Jan 2024filed 3 Jan 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,084 at $0.00 | filing |
| 4 Dec 2023filed 4 Dec 2023 | ERAS ErascaBiotechnology | SEC FORM 4 Bought | $50K30,000 at $1.66 | filing |
| 22 Jun 2023filed 26 Jun 2023 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | Sientra | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 10 Apr 2023filed 11 Apr 2023 | ERAS ErascaBiotechnology | SEC FORM 4 Bought | $55K20,000 at $2.76 | filing |
| 15 Dec 2022filed 15 Dec 2022 | ERAS ErascaBiotechnology | SEC FORM 4 Bought | $97K20,000 at $4.87 | filing |
| 1 Jul 2022filed 6 Jul 2022 | ERAS ErascaBiotechnology | SEC FORM 4 Code J | —750,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 20 Jul 2021filed 20 Jul 2021 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code C | —180,000 | filing |
| 20 Jul 2021filed 20 Jul 2021 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code C | —900,000 | filing |
| 20 Jul 2021filed 20 Jul 2021 | ERAS ErascaBiotechnology | SEC FORM 4 Code C | —150,000 | filing |
| 20 Jul 2021filed 20 Jul 2021 | ERAS ErascaBiotechnology | SEC FORM 4 Code C | —750,000 | filing |
News
No headline names them, or the companies they trade most, lately.